If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
JUNE 2012
Pathways
THE CLINICAL TRIALS NETWORK NEWSLETTER
Table of
Contents
2 CTN Expands
Collaboration with
SNMTS
CTN at a Glance
3 Biomarker Spotlight:
Flurpiridaz
4 FDA Guidance on PET
INDs
NIH Website on Clinical
Trials
CTN Co-sponsors
Industry Meeting
5 AM Educational
Opportunities
CTN Webinars
EARL and CTN Plan
Collaboration
6 Career Development
Research Essentials and
Tech Tip
7 Cardiovascular Imaging
Agents
8 CTN Cardiac Phantom
Revisited
Save the Dates
FDA Audits and Inspections for PET:
A Personal Perspective
Steve Zigler, PhD and Nancy Taylor, MS, RAC
Siemens PETNET Solutions
The regulation of PET in the United States was FDA inspector
JUNE 2012 Pathways
FDA Audits and Inspections Continued from page 1.
BIOMARKER SPOTLIGHT F-18 FLURPIRIDAZ MYOCARDIAL P
In the NEWS New Draft Guidance Issued on INDs fo
Annual Meeting Highlights Clinical Trials Net
Tech Talk: New Career Direction for Nuclear Medic
Special FEATURE CARDIOVASCULAR NUCLEAR IMAGING: T
CTN Cardiac Phantom Revisited Paul E. Christian,